Qurient Co

Qurient Co ROCE

The Return on Capital Employed (ROCE) of Qurient Co (115180.KQ) as of Oct 31, 2026 is -75.93 %. In the previous year, Return on Capital Employed (ROCE) was -47.71 % — a change of 59.16% (lower).

ROCE

-75.93 %

YoY

59.16%

Last updated:

In 2025, Qurient Co's return on capital employed (ROCE) was -75.93 %, a 59.16% increase from the -47.71 % ROCE in the previous year.

The Qurient Co ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-42.35 KRW
Jan 1, 2019
-133.33 KRW
Jan 1, 2020
-37.17 KRW
Jan 1, 2021
-44.83 KRW
Jan 1, 2022
-78.19 KRW
Jan 1, 2023
-49.79 KRW
Jan 1, 2024
-47.71 KRW
Jan 1, 2025
-75.93 KRW
The Qurient Co ROCE history
YEARROCEYoY
-75.93 %+59.16%
-47.71 %-4.19%
-49.79 %-36.32%
-78.19 %+74.42%
-44.83 %+20.62%
-37.17 %-72.12%
-133.33 %+214.83%
-42.35 %-51.63%
-87.55 %+92.46%
-45.49 %-84.00%
-284.40 %-1,027.90%
30.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Qurient Co Stock analysis

What does Qurient Co do? Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options. Qurient Co is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Qurient Co's Return on Capital Employed (ROCE)

Qurient Co's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Qurient Co's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Qurient Co's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Qurient Co’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Qurient Co stock

Return on Capital Employed (ROCE) of Qurient Co is -75.93 % in 2025.

Return on Capital Employed (ROCE) of Qurient Co changed from -47.71 % to -75.93 %, representing a 59.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Qurient Co since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Qurient Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Qurient Co

All Key Metrics — Qurient Co